BACKGROUND: Partial nephrectomy (PN) is recommended for localized T1a (4 cm) renal masses and is preferred over radical nephrectomy (RN) for amenable T1b/T2 (>4 cm) tumors. The objective of the current study was to assess overall survival (OS) differences between PN and RN in patients with T1 and T2 renal cell carcinoma (RCC). METHODS: The National Cancer Data Base was queried for patients with T1 and T2 RCC who underwent PN or RN from 2004 to 2014. Trends in surgery were evaluated using Cochran-Armitage tests. Differences in OS were assessed using adjusted Kaplan-Meier methods. The effects of procedure on OS were analyzed using propensity scorebased, weighted Cox proportional hazards models. RESULTS: In total, 212,016 patients with T1 and T2 RCC who underwent either RN (59.7%) or PN (40.3%) were included. The use of PN rose from 2004 to 2014 (T1a: from 40.6% to 71.4%; T1b/T2: from 8.4% to 26.5%; P <.01). Adjusted 5-year OS was longer for patients who underwent PN in both subsets, although effect magnitude was reduced in the T1b/T2 cohort (T1a: 89.6% vs 85.1%; hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.70-0.75; P <.01; T1b/T2: 82.5% vs 80.8%; HR, 0.88; 95% CI, 0.83-0.94; P 5.01). The benefit of PN on OS diminished as age and time from diagnosis increased; no OS improvement was observed in patients age 75 years who had T1b/T2 tumors (HR, 0.89; 95% CI, 0.76-1.06). CONCLUSIONS: Receipt of PN is associated with improved OS in patients with T1a RCC. No procedure-related differences in OS were observed for patients age 75 years who had tumors measuring >4 cm. Decisions to undergo PN for T1b/T2 tumors should be based on individualized risk assessment.
INTRODUCTION
In the United States, it is projected that kidney and renal pelvis cancers (majority renal cell carcinoma [RCC]) will account for 63,990 new cases and 14,400 total deaths in 2017. 1 In part because of the increased use of cross-sectional imaging, a rising incidence in RCC and its treatment has been observed. 2 Although ablation and active surveillance remain viable management strategies in select patients, existing guidelines recommend surgery as best practice for localized RCC in patients who have acceptable perioperative risk. 3, 4 The decision to perform partial nephrectomy (PN) or radical nephrectomy (RN) in patients with T1 and T2 renal masses is complicated by controversial and contradictory evidence. 5 Although few would argue against nephron-sparing surgery (NSS) in healthy patients with anatomically simple renal masses, clinical scenarios are rarely so straightforward. Instead, decision making pivots on a nuanced consideration of risks and benefits. 5 The only randomized, controlled trial comparing PN with RN demonstrated no difference in overall survival (OS) between PN and RN for patients who had with RCC tumors 5 cm in greatest dimension. 6 However, follow-up in the same cohort demonstrated a greater prevalence of chronic kidney disease (CKD) for patients who underwent RN. 7 Despite methodologic concerns, 8 these results highlight some of the inherent trade-offs between the 2 approaches.
Because it is unlikely that additional randomized trials are forthcoming, well controlled observational studies may be the only mechanism to inform the existing comparative effectiveness evidence base. 9 To date, observational analyses using Medicare data have reported conflicting survival results despite rigorously adjusting for selection bias using propensity D ata Base methods and instrumental variable approaches. [10] [11] [12] Although well designed, these studies are limited by restricting participation to patients age 65 years and including only 30% of new cancer diagnoses in the United States. In contrast, the National Cancer Data Base (NCDB) includes patients of all ages, captures 70% of all newly diagnosed cancers in the United States, and contains more than 34 million patient records. 13 Harnessing these advantages, our objective was to evaluate differences in OS for patients with localized T1 and T2 renal tumors who undergo PN and RN.
MATERIALS AND METHODS

Definitions
Data source
The NCDB, a program of the American College of Surgeons Commission on Cancer and the American Cancer Society, is a national cancer registry that was established in 1989 and compiles data from more than 1500 accredited cancer programs in the United States and Puerto Rico, capturing approximately 70% of all incident cancer cases. 13 
Cohort definition and outcome
Patients with RCC were identified in the NCDB based on ICD-O-3 site codes. We confined our analysis to individuals age 18 years who underwent PN or RN between 2004 and 2014 for stage I and II RCC (American Joint Commission on Cancer T1-T2N0M0). RCC cases were determined based on histologic subtypes: clear cell, papillary, chromophobe, sarcomatoid, or not otherwise specified/aggressive variant histologies. Patients who had non-RCC histology, had received treatment other than PN or RN, or had received any neoadjuvant therapy were excluded (Fig. 1) . The primary outcome measure was OS. Secondary outcomes included characteristics associated with the receipt of PN and temporal trends in treatment. 
Covariates
Patient socioeconomic characteristics were obtained from US Census tract data. Comorbidity was determined using the Charlson-Deyo comorbidity index (CCI) (categorized as scores of 0, 1, or 2). The NCDB classifies hospitals as unknown, community (100-500 new cancer cases per year), comprehensive community (>500 cases per year), and academic/research (defined by the National Cancer Institute designation or a medical school affiliation).
Statistical Analysis
Patients were stratified into 2 stage groups: T1a (4 cm) and T1b/T2 (>4 cm). Within groups, patient demographic and clinicopathologic characteristics were compared between those who underwent PN or RN using chisquare tests. Temporal trends in treatment were assessed using Cochran-Armitage tests. We examined the association between receipt of PN or RN and patient demographic/clinicopathologic factors across patients with any stage tumor using multivariable logistic regression adjusting for age, sex, race (white, black, or other), ethnicity (Hispanic, non-Hispanic, or unknown), year of diagnosis, comorbidities, urban/rural hospital, tumor (T)-classification, tumor histology, tumor grade (1 and 2 vs 3 and 4), facility location, facility type, income, education, and payer group. To account for clustering within hospitals, we used robust standard errors with generalized estimating equations.
14 Differences in OS by treatment were evaluated separately for the T1a and T1b/T2 groups. We used a propensity-score inverse probability of treatment weighting approach, 15 estimating the probability of receiving PN based on patient and tumor factors through logistic regression. We assessed postadjustment covariate balance using weighted chi-square tests. The relation between PN/RN and OS was evaluated using weighted KaplanMeier curves and Cox proportional hazards regression models. P values and 95% confidence intervals (CIs) values were calculated using bootstrap methods. To consider the impact of age and time from diagnosis on OS, we allowed for time-varying effects of surgery in the Cox models to estimate hazard ratios (HRs) for the effect of PN at 0 to 2 months, 12 to 36 months, 36 to 60 months, and 60 months after diagnosis stratified by age group and including a time-by-age interaction term. For statistical analysis, we used the software packages SAS (version 9.3; SAS Institute, Inc, Cary, NC) and R (version 3.1; R Foundation for Statistical Computing, Vienna, Austria), with P < .05 considered statistically significant.
RESULTS
Cohort Characteristics
We identified 212,016 patients with a mean 6 standard deviation age of 60.4 6 12.6 years who underwent surgery for T1 and T2 RCC between 2004 and 2014 (Table 1 ). In the T1a cohort, 73,378 patients (59.7%) underwent PN; and 16,698 PNs (18.8%) were performed in the T1b/T2 group. For patients who had both T1a and T1b/ T2 tumors, significant differences at baseline between PN and RN were observed with respect to age, sex, race, ethnicity, year of diagnosis, CCI, urban/rural hospital, tumor histology, tumor grade, facility location, facility type, patient income level, and insurance type (P < .05 for all) ( Table 1) . 
Survival Differences in PN Versus RN/Ristau et al
Survival Analyses
OS was higher in patients who underwent PN for those who had T1a and T1b/T2 tumors (Fig. 3) . These differences were attenuated but remained significant after adjustment by propensity score weighting. The 5-year adjusted OS rate for patients with T1a tumors was 89.6% for PN and 85.1% for RN (P < .01). For patients who had T1b/T2 tumors, the 5-year adjusted OS rate was 82.5% for PN and 80.8% for RN (P 5 .01). Propensity score-adjusted models demonstrated superior OS for patients with T1a tumors who underwent PN versus RN (HR, 0.73; 95% CI, 0.70-0.75) ( Table 3) . Although it was still statistically significant, the OS benefit for patients who underwent PN in the T1b/T2 cohort was smaller (HR, 0.88; 95% CI, 0.83-0.94).
When the analysis was stratified by time from diagnosis and age, an OS benefit favored PN over RN in T1a tumors for nearly all patient age groups at all time points from diagnosis. PN conferred the most pronounced OS benefit in patients ages 18 to 44 years who had T1a tumors (60 months after diagnosis: HR, 0.63; 95% CI, 0.52-0.74) (Fig. 4) . A notable exception was in patients age 75 years, who did not benefit from PN at time points >5 years after diagnosis (HR, 0.97; 95% CI, 0.90-1.06).
The improved OS associated with PN in the T1a cohort was more age-dependent in the T1b/T2 group (Fig. 4) . For younger patients (ages 18-44 and 45-64 years), an OS benefit was observed for PN over RN at all time points. However, although improvements in OS favoring PN were observed up to 1 year after diagnosis for patients ages 65 to 74 years (HR, 0.84, CI 0.72-0.99), there was no difference in OS for PN relative to RN at 3 years (HR, 0.88; 95% CI, 0.78-1.00) or at 5 years (HR, 0.97; 95% CI, 0.86-1.13) postdiagnosis. OS between PN Abbreviations: CI, confidence interval; NOS, not otherwise specified; OR, odds ratio; PN, partial nephrectomy; RCC, renal cell carcinoma.
and RN was not different in patients age 75 years who had T1b/T2 tumors at any time point.
DISCUSSION
The increased detection of renal masses over the past 2 decades has contributed to a greater number of kidney surgeries being performed. 2 Although the uptake of NSS historically has been slow, 16 the current data corroborate prior findings 17 and demonstrate a trend toward increased use of PN in T1 and T2 tumors across all age groups, with >70% of patients with T1a tumors and 26% of those with T1b tumors receiving PN in 2014.
Despite its increased use, it remains unclear whether the survival advantages associated with PN 18, 19 are applicable to all patients who present with localized renal tumors, because selection biases (including unmeasured confounders) markedly limit prior conclusions. Proponents of "nephron-sparing for all" cite the importance of renal preservation in minimizing downstream CKD and associated mortality. 20, 21 Yet contentious debate persists regarding the generalizability of surgically associated CKD (CKD-S) to medically associated CKD (CKD-M) and its inherent sequelae. 22 Randomized trial evidence 6 conflicts with well conducted observational analyses [10] [11] [12] and further complicates the urologists ability to inform patients with T1 and T2 renal masses on what is "the right thing to do." 5 Our analysis builds on existing knowledge by including patients age <65 years and increases generalizability through capturing all payers and a larger number of patients relative to prior Medicare-based analyses. [10] [11] [12] [13] For virtually all patients with T1a tumors, a statistically significant improvement in OS was noted favoring PN. Although it still was present, this improvement in OS for PN was tempered with older age and increasing time after from diagnosis. Furthermore, no differences in OS were observed between PN and RN for T1a tumors in the oldest cohort (ages 75 years) at 5 or more years after diagnosis, a finding consistent with prior reports.
12 Although these differences are indeed statistically significant, the absolute difference in 5-year OS favoring PN was only 4.5% (89.6% vs 85.1%) in the T1a group and 1.7% (82.5% vs 82.8%) in the T1b/T2 group. These small absolute differences, coupled with an inability to control completely for all confounders, highlight the nuance associated with surgical decision making in patients with localized RCC.
In the T1b/T2 group, we observed an OS benefit favoring PN for the youngest patients (ages 18-44 and 45-64 years) at all time points after diagnosis. This finding supports a recent meta-analysis by Mir and colleagues in which patients who underwent PN for T1b/T2 kidney tumors had improved OS relative to those who underwent RN. 23 However, again, these differences were reduced in older patients and as time intervals from diagnosis increased. Whereas an OS benefit was noted in patients ages 65 to 74 years up to 1 year after diagnosis, no difference in OS was observed for PN relative to RN at 5 years. Furthermore, we did not demonstrate any differences in OS between PN and RN at any time point for patients age 75 years who had T1b/T2 tumors. The tempered OS benefit for PN in older patients may occur because the accrued benefits of NSS are outweighed by other competing risks to mortality. 24 The finding that the PN-associated OS benefit diminishes with increasing time from diagnosis runs counter to the common argument that choosing PN over RN protects patients from long-term CKD-associated mortality. 25 One explanation may be recent data underscoring the important distinction between CKD-S and CKD-M
22
; namely, patients with CKD-S experience greater stability in renal function and improved survival after surgery than patients with concomitant CKD-M. It is noteworthy that we observed attenuated OS trends favoring PN similar to those previously reported by Lane and colleagues. 22 These findings are bolstered by evidence demonstrating that nearly one-half of patients who undergo RN recover their estimated glomerular filtration rate by 2 years after surgery 26 and are corroborated by reports supporting preserved long-term renal function after donor nephrectomy. 27 Taken together, these data may help explain why the observed OS benefit for PN relative to RN is smaller than previously believed for some patients. Prevention of CKD is a critical consideration. Our analysis supports existing recommendations that PN should be the preferred approach in patients with T1a renal masses who are acceptable operative candidates. However, the decision to perform PN in patients with T1b/T2 tumors is less clear. Imperative reasons for PN certainly exist (eg, solitary kidney, significant CKD, etc), and our data support consideration of elective PN in patients age <65 years with amenable T1b and T2 tumors. Yet these benefits must be balanced with the increased oncologic potential of larger tumors 28 and the elevated risk of perioperative complications inherent to more complex surgeries. 5, 6 Current clinical guidelines suggest that RN may be preferable in highly complex tumors when no preoperative CKD or proteinuria exists, the contralateral kidney appears normal, the predicted estimated glomerular filtration rate after RN is >45 mL/ minute/1.73 m 2 , and PN would be challenging even in experienced hands. 4 Although a clinical trial in this subset would be ideal to answer these questions, 29 concerns regarding accrual challenges preclude activation. Thus, we are left with observational analyses and their associated selection biases to balance trade-offs between PN and RN. 5 The principle limitation of our study is its observational design; thus, the impact of unmeasured confounding inherent to selection biases cannot be completely excluded. 9 For example, removing patients who are upstaged to pathologic T3 disease could make PN appear more favorable, because upstaged patients are likely to benefit more from RN. However, upstaging would most likely occur in patients with clinical T1b/T2 disease-the population in which the observed benefit of PN was tempered. Furthermore, important clinical considerations, such as tumor complexity, renal mass biopsy results, and preoperative renal function, are not available in the NCDB. Moreover, cause of death data were not available, precluding us from classifying mortality as cancer-specific, CKD-associated, or other-cause. Finally, NCDB data are not granular enough to account for selection biases associated with surgeon-specific case volumes. However, the NCDB does provide a large sample, allpayer registry of adult cancer cases, making our findings more generalizable than prior reports and affording the ability to detect small and time-varying effects. Moreover, we used propensity score weighting to control for all available prognostic variables and to balance patients who underwent PN and RN. Although previous studies comparing PN with RN have used instrumental variable analyses to adjust for unmeasured confounding, 11 we were unable to use this approach because there was no strong instrument available (a frequent problem for instrumental variable analyses 30 ). Without a strong, valid instrument, propensity score methods are preferable, because instrumental variable methods may be biased or underpowered.
Conclusion
Our analysis demonstrates an association between receipt of PN and improved OS for all patients who had T1a RCC identified in the NCDB. However, survival differences were diminished in patients with T1b/T2 tumors, and no advantage for PN was observed for patients age 75 years in this subset. The choice of surgical approach in patients with larger tumors should be driven by a thorough discussion of individualized risks and benefits.
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